Intec Pharma Ltd. 8-K 2008
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Neose Technologies, Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
At a meeting held on February 4, 2008, the Compensation Committee (the "Committee") of the Board of Directors of Neose Technologies, Inc. (the "Company") determined the 2007 bonuses for the Company’s executive officers (the "Executive Officers") under the Company’s bonus program (previously described in the Company’s Current Report on Form 8-K filed with the SEC on February 3, 2006, the "Bonus Program") in the following amounts: George J. Vergis, President and Chief Executive Officer: $136,500.00; Debra J. Poul, Senior Vice President, General Counsel and Secretary: $84,895.35; A. Brian Davis, Senior Vice President and Chief Financial Officer: $67,600.00; Bruce A. Wallin, Senior Vice President, Clinical Development and Chief Medical Officer: $60,420.44; and Valerie M. Mulligan, Senior Vice President, Quality and Regulatory Affairs: $59,676.84.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.